TRVI News and Press, Trevi Therapeutics Inc. From 06/30/22

3 Trending Penny Stocks to Watch as June Ends Finding trending penny stocks to buy is not easy. Especially when we consider how much is going on in the stock market as of late, trending penny stocks are not easy to come by. However, with the right research on hand, we can find plent...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Spyro the Dragon / Shutterstock.com Palantir (NYSE: PLTR ) stock is slipping on Wednesday as investors remained unimpressed with two new projects revealed by the data analytics company. First up is a c...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Trevi Therapeutics (NASDAQ: TRVI ) stock is flying higher on Wednesday following the release of positive clinical trial data ! This data comes from the company’s Phase 2b/3 Pruritu...

The GDP report is out, and not much has changed in the overall stock market after yesterday’s sell-off. The S&P 500 (NYSEARCA: SPY ) closed at $380.65, and following the GDP report, the SPY sits within 20 cents of that figure. Whether or not there is a rebound in the stock ma...

Gainers: Allena Pharmaceuticals ( ALNA ) +238% . Trevi Therapeutics TRVI +29% . Bellerophon Therapeutics ( BLPH ) +22% . Agenus ( AGEN ) +21% . Catalyst Biosciences CBIO +18% . Losers: Agile Therapeutics ( AGRX ) -29% . ...

Trevi Therapeutics ( NASDAQ: TRVI ) added ~29% in the pre-market Wednesday after the clinical-stage biopharmaceutical company said that the pain therapy Haduvio met key goals in a Phase 2b/3 study involving patients with prurigo nodularis, a dermatological condition. The...

Trevi Therapeutics ( TRVI ) +36% reports positive results from the Ph2b/3 PRISM trial of Haduvio in the treatment of Prurigo nodularis. Catalyst Biosciences CBIO +26% plans to distribute $65M cash to stockholders. 2U TWOU +18% as Byju's reportedly mak...

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis PR Newswire Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured by ...

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention PR Newswire NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical...

Oppenheimer has begun Trevi Therapeutics (NASDAQ:TRVI) with an overweight rating citing the potential of its candidate Haduvio (nalbuphine ER) specifically for chronic cough associated with idiopathic pulmonary fibrosis. Haduvio is in phase 2 for that indication. It is also in phase 2 for chr...